Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Closing in on the truth about recombinant human bone morphogenetic protein-2: evidence synthesis, data sharing, peer review, and reproducible research.

Laine C, Guallar E, Mulrow C, Taichman DB, Cornell JE, Cotton D, Griswold ME, Localio AR, Meibohm AR, Stack CB, Williams SV, Goodman SN.

Ann Intern Med. 2013 Jun 18;158(12):916-8. doi: 10.7326/0003-4819-158-12-201306180-00012. No abstract available.

PMID:
23778911
2.

The changing structure of industry-sponsored clinical research: pioneering data sharing and transparency.

Kuntz RE.

Ann Intern Med. 2013 Jun 18;158(12):914-5. doi: 10.7326/0003-4819-158-12-201306180-00011. No abstract available.

PMID:
23778910
3.

Meta-analysis of trials of recombinant human bone morphogenetic protein-2: what should spine surgeons and their patients do with this information?

Resnick D, Bozic KJ.

Ann Intern Med. 2013 Jun 18;158(12):912-3. doi: 10.7326/0003-4819-158-12-201306180-00010. No abstract available.

PMID:
23778909
4.

A historic moment for open science: the Yale University Open Data Access project and medtronic.

Krumholz HM, Ross JS, Gross CP, Emanuel EJ, Hodshon B, Ritchie JD, Low JB, Lehman R.

Ann Intern Med. 2013 Jun 18;158(12):910-1. doi: 10.7326/0003-4819-158-12-201306180-00009. No abstract available.

5.

Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis.

Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, Helfand M.

Ann Intern Med. 2013 Jun 18;158(12):890-902. doi: 10.7326/0003-4819-158-12-201306180-00006. Review.

PMID:
23778906
6.

YODA and truth seeking in medicine.

Doshi P, Vedula SS, Li T.

BMJ. 2013 Jul 2;347:f4251. doi: 10.1136/bmj.f4251. No abstract available.

PMID:
23819966
7.

Editorial: Recombinant human bone morphogenetic protein-2.

Shaffrey CI, Smith JS.

J Neurosurg Spine. 2013 Feb;18(2):109-10; discussion 110-1. doi: 10.3171/2012.9.SPINE12476. Epub 2012 Nov 30. No abstract available.

PMID:
23198758
8.

Medtronic submits full data on spinal protein to independent scrutiny.

Cohen D.

BMJ. 2011 Aug 30;343:d5484. doi: 10.1136/bmj.d5484. No abstract available.

PMID:
21878463
9.

Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine.

Burkus JK, Gornet MF, Glassman SD, Slosar PJ, Rosner MK, Deckey JE, Nowak J, Hatcher BM.

Spine (Phila Pa 1976). 2011 Dec 1;36(25):2158-67. doi: 10.1097/BRS.0b013e3182059a8c.

PMID:
21325990
10.

Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data.

Simmonds MC, Brown JV, Heirs MK, Higgins JP, Mannion RJ, Rodgers MA, Stewart LA.

Ann Intern Med. 2013 Jun 18;158(12):877-89. doi: 10.7326/0003-4819-158-12-201306180-00005.

PMID:
23778905
11.

A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.

Carragee EJ, Hurwitz EL, Weiner BK.

Spine J. 2011 Jun;11(6):471-91. doi: 10.1016/j.spinee.2011.04.023. Review.

PMID:
21729796
12.

Seroma observed 6 months after anterior lumbar interbody fusion that included use of recombinant bone morphogenetic protein 2.

Scheer JK, Dahdaleh NS, Smith ZA.

Spine J. 2015 Oct 1;15(10):e33. doi: 10.1016/j.spinee.2015.05.033. Epub 2015 May 27. No abstract available.

PMID:
26022670
13.

Folly of FDA-approval studies for bone morphogenetic protein.

Mirza SK.

Spine J. 2011 Jun;11(6):495-9. doi: 10.1016/j.spinee.2011.05.009. No abstract available.

PMID:
21729798
14.

Exposing conflicts of interest and complications of rhBMP-2.

Chi JH.

Neurosurgery. 2011 Oct;69(4):N21-2. doi: 10.1227/01.neu.0000405599.24202.aa. No abstract available.

PMID:
21900807
15.

Resetting standards for sponsored research: do conflicts influence results?

Spengler DM.

Spine J. 2011 Jun;11(6):492-4. doi: 10.1016/j.spinee.2011.05.001. No abstract available.

PMID:
21729797
16.

A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors.

Carragee EJ, Ghanayem AJ, Weiner BK, Rothman DJ, Bono CM.

Spine J. 2011 Jun;11(6):463-8. doi: 10.1016/j.spinee.2011.06.001. No abstract available.

PMID:
21729794
17.

Symptomatic heterotopic bone formation after rhBMP-2 utilization in lateral lumbar interbody fusion.

Aichmair A, Girardi FP, Hughes AP, Sama AA, Lebl DR, Cammisa FP.

Spine J. 2013 Oct;13(10):1411-2. doi: 10.1016/j.spinee.2013.07.473. Epub 2013 Oct 18. No abstract available.

PMID:
24139750
18.

Reply to "A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned".

Dimar JR 2nd, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY.

Spine J. 2011 Nov;11(11):1082-3; author reply 1083-6. doi: 10.1016/j.spinee.2011.09.029. Epub 2011 Nov 11. No abstract available.

PMID:
22078853
19.

Re: A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.

Woo EJ.

Spine J. 2011 Aug;11(8):804; author reply 804-5. doi: 10.1016/j.spinee.2011.08.001. No abstract available.

PMID:
21925424
20.

Letter to the editor regarding "A critical review of recombinant human morphogenetic protein-2 trials in spine surgery: emerging safety concerns and lessons learned".

Anderson PA.

Spine J. 2012 Apr;12(4):356; author reply 356-7; discussion 357-9. doi: 10.1016/j.spinee.2012.03.005. Epub 2012 Mar 28. No abstract available.

PMID:
22464143

Supplemental Content

Support Center